S-1: Windtree Therapeutics Files for Resale of Up to 42.2 Million Shares Following Preferred Stock Conversion

Windtree Therapeutics is registering for the resale of up to 42,168,035 shares of its common stock, issuable upon conversion of Series D convertible preferred stock held by selling stockholders.

Summary

• Windtree Therapeutics has filed a registration statement for the resale of up to 42,168,035 shares of common stock.
• These shares are issuable upon the conversion of Series D convertible preferred stock held by selling stockholders.
• The preferred shares were acquired under a securities purchase agreement dated April 29, 2025.
• Windtree will not receive any proceeds from the sale of these shares by the selling stockholders.
• The company is registering the resale as required by a registration rights agreement.
• The selling stockholders may sell the shares at fixed, market, or negotiated prices.
• A reverse stock split of 1-for-50 was previously implemented, effective February 20, 2025.
• The last reported sale price of Windtree's common stock on Nasdaq on May 15, 2025, was $0.83 per share.
• Windtree is a smaller reporting company and has elected to comply with reduced reporting requirements.
• The company has incurred operating losses since its incorporation in 1992, with operating losses of $26.1 million and $20.6 million for the years ended December 31, 2024 and 2023, respectively.
• As of December 31, 2024, Windtree had an accumulated deficit of $846.6 million and cash and cash equivalents of $1.8 million.
• The company's ability to continue as a going concern is dependent on securing additional capital.
• A private placement of Series D Preferred Stock for approximately $2.5 million in gross proceeds occurred on April 29, 2025.
• The initial conversion price of the Series D Preferred Stock is $1.368, subject to adjustment to no lower than $0.274.
• The company agreed to seek stockholder approval for the issuance of common stock upon conversion of the Preferred Shares.
• Until stockholder approval is received, the company cannot issue shares exceeding 19.99% of its outstanding common stock prior to the private placement.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the private placement and new corporate strategy, the significant operating losses, accumulated deficit, and going concern uncertainty weigh heavily on the overall outlook.

Positives

• The private placement of Series D Preferred Stock provides Windtree with approximately $2.5 million in gross proceeds.
• The company is actively pursuing a new corporate strategy to become a revenue-generating biotech company through acquisitions.
• Windtree has commercialization expertise in both large pharmaceutical and small biotech companies across multiple therapeutic areas.
• The company has a regional licensed partnership with Lees Pharmaceutical (HK) Ltd. for the development and commercialization of istaroxime in Greater China.

Negatives

• Windtree has incurred significant operating losses since its incorporation and expects to continue to incur losses in the future.
• The company's current cash position raises substantial doubt about its ability to continue as a going concern.
• The company is dependent on securing additional capital to advance its development programs.
• The company may be forced to limit or cease its development activities if it cannot secure additional funding.
• The sale of a substantial number of shares by the selling stockholders could cause the price of Windtree's common stock to decline.
• Stockholder dilution may occur as a result of future equity offerings and other issuances of securities.

Risks

• A sale of a substantial number of shares of common stock by the selling stockholders could cause the price of Windtree's common stock to decline.
• Future equity offerings and other issuances of securities may result in stockholder dilution.
• Windtree's current cash resources will not be sufficient to fund its research and development efforts.
• The company's current cash position, losses, negative cash flows from operations, and accumulated deficit raise substantial doubt about its ability to continue as a going concern.
• Restrictive covenants under the PIPE Purchase Agreements may make it difficult to procure additional financing.
• The company may not be able to achieve or sustain profitability.
• Delays and uncertainties in anticipated timelines and milestones and additional costs associated with geopolitical events could impact clinical trial operations.
• The company's ability to successfully implement its new business strategy to generate revenue through acquisitions of small companies and their FDA-approved products is uncertain.

Future Outlook

Windtree expects to continue to incur significant research and clinical development, regulatory and other expenses as it continues to develop its product candidates, seeks regulatory clearances or approvals, conducts clinical trials, and manufactures, markets, and sells any product candidates for which it may obtain regulatory approval. The company is also pursuing a new corporate strategy to become a revenue-generating biotech company through acquisitions.

Industry Context

The document highlights the challenges faced by small biotech companies in maximizing the commercialization potential of their FDA-approved products, which Windtree aims to capitalize on through acquisitions. This reflects a broader trend in the biotech industry where smaller companies often struggle to compete with larger pharmaceutical firms and may seek acquisition as a means to realize value.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• However, it mentions Windtree's intention to acquire small companies with FDA-approved products, which suggests a strategy similar to that of some pharmaceutical companies that grow through acquisitions of smaller biotech firms with promising assets.
• Without specific financial metrics or performance data, it is difficult to assess Windtree's results in the context of global benchmarks.

Stakeholder Impact

• Shareholders may experience dilution as a result of future equity offerings.
• Employees' job security may be affected if the company is forced to limit or cease its development activities.
• The company's ability to meet its obligations to creditors may be affected by its financial condition.
• The company's ability to develop and commercialize its product candidates may be affected by its financial condition.

Next Steps

• Seek stockholder approval for the issuance of common stock upon conversion of the Preferred Shares.
• Continue to develop product candidates and seek regulatory clearances or approvals.
• Pursue strategic opportunities, including licensing agreements and acquisitions of small companies.
• Secure additional capital through public or private securities offerings, convertible debt financings, and/or strategic opportunities.

Key Dates

Keywords

Windtree Therapeutics, common stock, Series D Preferred Stock, resale, registration statement, istaroxime, cardiogenic shock, acute heart failure, private placement, reverse stock split, SEISMiC Study, SEISMiC Extension, SEISMiC C Study, aPKCi inhibitor, rostafuroxin, biotechnology, financing, capital raise